Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

JP Morgan Upgrades Allergan


JP Morgan upgrades specialty global health care company Allergan (AGN) to overweight from neutral.

Analyst Corey Davis says after nearly two years of neutrality, he upgrades. He says this is not a "trade around an event" upgrade, nor even a catalyst-driven story.

He envisions a three-year investment time horizon with substantial and steady returns in each of those years driven by consistent, possibly even accelerating earnings growth, with little or no risk.

Cory finds the current multiple reasonable. While he cannot argue the company is trading at a discount to the group or market, he could argue it trades at a substantial discount to Alcon, with a better growth rate and earnings per share potential.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus